Showing results (31-40 of 42) with videos related to
Sort By:
Pageof 5
Annals of Gastroenterology|January 30, 2026
Immune-mediated diarrhea and colitis with normal biochemical, endoscopic and histologic findings: a retrospective studyMalek Shatila, Sharada Wali, Carolina Colli Cruz, et al.Critical Reviews in Oncology/Hematology|November 25, 2023
Antibody drug conjugates in older patients: State of the artLayal Rached, Arthur Geraud, Maxime Frelaut, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 23, 2023
Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I StudyLuis Paz-Ares, Stephane Champiat, W Victoria Lai, et al.Lung Cancer (Amsterdam, Netherlands)|December 10, 2025
A multi-institutional perspective on tarlatamab administration and management of CRS/ICANSBingnan Zhang, Laura Alder, Samuel Rosner, et al.JAMA Oncology|September 8, 2018
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2025
A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid TumorsOliver Bechter, Carmen Loquai, Stephane Champiat, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 6, 2024
Phase II Study to Determine the Antitumor Activity and Safety of Simlukafusp Alfa (FAP-IL2v) Combined with Atezolizumab in Esophageal CancerHans Prenen, Sanjeev Deva, Bhumsuk Keam, et al.The Oncologist|March 14, 2026
Telemedicine as a Gateway to Early-Phase Oncology Trials: Lessons from 14,000 Patients and Future Directions for Global Access and EquityCarlos Torrado, Clark R Andersen, Lei Kang, et al.JCO Precision Oncology|January 20, 2022
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non-Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or ChemotherapyRoberto Ferrara, Laura Mezquita, Matthieu Texier, et al.Journal for Immunotherapy of Cancer|May 16, 2022
Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockadeCarlos Gomez-Roca, Philippe Cassier, Dmitriy Zamarin, et al.Pageof 5